EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Beam Therapeutics's enterprise value is $854.5 Mil.
Beam Therapeutics's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $377.7 Mil. Therefore, Beam Therapeutics's EV-to-Revenue for today is 2.26.
The historical rank and industry rank for Beam Therapeutics's EV-to-Revenue or its related term are showing as below:
BEAM'
s EV-to-Revenue Range Over the Past 10 Years
Min: 2.18 Med: 22.8 Max: 6950.67
Current: 2.26
During the past 7 years, the highest EV-to-Revenue of Beam Therapeutics was 6950.67. The lowest was 2.18. And the median was 22.80.
BEAM's EV-to-Revenue is ranked better than 75.12% of 1033
companies
in the Biotechnology industry
Industry Median: 7.63
vs BEAM: 2.26
The historical data trend for Beam Therapeutics's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Beam Therapeutics's EV-to-Revenue
For the Biotechnology subindustry, Beam Therapeutics's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Beam Therapeutics's EV-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Beam Therapeutics's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Beam Therapeutics's EV-to-Revenue falls into.
Beam Therapeutics's current Enterprise Value is $854.5 Mil.
Beam Therapeutics's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $377.7 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Beam Therapeutics's share price for today is $21.60.
Beam Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $4.73.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Beam Therapeutics EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of Beam Therapeutics's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Beam Therapeutics (Beam Therapeutics) Business Description
Beam Therapeutics Inc is a biotechnology company engaged in creating genetic medicines based on its base editing technology. This technology enables a new class of genetic medicines that targets a single base in the genome without making a double-stranded break in the DNA. The company's portfolio comprises Gene Correction, Gene Modification, Gene Activation, Gene Silencing, and Multiplex Editing.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
BEAM has been successfully added to your 